Gene · 51645
Papers1,304
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,304
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Pin1-cis P-tau Axis: A Key Common Early Pathogenic Driver, Biomarker and Therapeutic Target Across Neurodegenerative, Traumatic, and Vascular Cognitive Disorders. | Cells | 2026 | 42782751 | PubTator, text mining | PubMed |
| Pin1 in cancer: Signaling mechanisms, structural basis and advances in inhibitor development. | Eur J Med Chem | 2026 | 42480355 | PubTator, text mining | PubMed |
| Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses. | Antimicrob Agents Chemother | 2026 | 42467054 | PubTator, text mining | PubMed |
| Peptidyl-prolyl isomerase B suppresses BEFV- and VSV-induced type I interferon responses via degradation of PBLD. | Vet Microbiol | 2026 | 42456219 | PubTator, text mining | PubMed |
| PIN1 inhibits ferroptosis in gastric cancer cells by regulating the CPEB1‑GPX4 pathway. | Oncol Rep | 2026 | 42438262 | PubTator, text mining | PubMed |
| Structure-Based Discovery of (E)- and (Z)-4-Oxobut-2-enoate Derivatives as Novel Covalent Pin1 Inhibitors with Antitumor Activity. | J Med Chem | 2026 | 42388100 | PubTator, text mining | PubMed |
| From Scaffold to Therapy: Benzimidazole Pharmacophore Evolution in Breast Cancer Research. | Chem Biodivers | 2026 | 42127228 | PubTator, text mining | PubMed |
| Systematic Optimization of Proteolysis-Targeting Chimeras for PIN1 Enables Selective Degradation and Antitumor Activity In Vivo. | Pharmaceutics | 2026 | 41900774 | PubTator, text mining | PubMed |
| Causal relationship between genetically predicted Enzyme and Tinnitus risk: a two-sample bi-directional mendelian randomization study. | Braz J Otorhinolaryngol | 2026 | 41895103 | PubTator, text mining | PubMed |
| IgE to cyclophilin Bet v 7 triggers mast cell activation and mediates cross-reactivity with Ara h 18 in children with seasonal allergic rhinitis. | Pediatr Allergy Immunol | 2026 | 41781362 | PubTator, text mining | PubMed |
| Exploring potential biomarkers of diffuse large B-cell lymphoma through multi-dimensional data. | Clin Transl Oncol | 2026 | 41739400 | PubTator, text mining | PubMed |
| Folding Thermodynamics and Kinetics of the N-Terminal Domain of the Circadian Clock-Regulated Histidine Kinase SasA. | Chembiochem | 2026 | 41730047 | PubTator, text mining | PubMed |
| Effect of a standardized meal on inflammatory biomarkers. | Scand J Clin Lab Invest | 2026 | 41689559 | PubTator, text mining | PubMed |
| Isothiocyanate-mediated cyclization of phage-displayed peptides enables discovery of macrocyclic binders. | Sci Adv | 2026 | 41650271 | PubTator, text mining | PubMed |
| Based on 3D-QSAR modeling and molecular dynamics of novel peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 inhibitors design and screening. | Medicine (Baltimore) | 2026 | 41578563 | PubTator, text mining | PubMed |
| PPIL1 promotes hepatocellular carcinoma progression and associates with poor prognosis. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 41528450 | PubTator, text mining | PubMed |
| The peptidyl-prolyl cis-trans isomerase, Pin1, is a regulator of the protein kinase C θ (PKCθ) catalytic activity in activated T cells. | Protein Sci | 2026 | 41427722 | PubTator, text mining | PubMed |
| Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses. | J Adv Res | 2026 | 40783069 | PubTator, text mining | PubMed |
| Mouse genome engineering uncovers 18 genes dispensable for male reproduction. | Andrology | 2026 | 40572022 | PubTator, text mining | PubMed |
| Scaffold Hopping and Optimization of Thiazole Hybrids as Selective PIN1 Inhibitors: A Computational Study. | Med Chem | 2026 | 40265424 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51645/papers